Alliance Wealth Advisors LLC UT lifted its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 412.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,853 shares of the company’s stock after buying an additional 21,611 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Novo Nordisk A/S were worth $2,442,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Stone House Investment Management LLC increased its stake in shares of Novo Nordisk A/S by 55.3% in the second quarter. Stone House Investment Management LLC now owns 177 shares of the company’s stock valued at $29,000 after purchasing an additional 63 shares during the period. Cornerstone Planning Group LLC acquired a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $29,000. Tower Research Capital LLC TRC boosted its stake in shares of Novo Nordisk A/S by 165.3% during the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after buying an additional 124 shares during the period. Lee Financial Co acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $32,000. Finally, Steward Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $37,000. 6.41% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Trading Down 0.9 %
Shares of Novo Nordisk A/S stock opened at $120.15 on Monday. Novo Nordisk A/S has a 12-month low of $67.66 and a 12-month high of $121.65. The company has a market cap of $539.18 billion, a price-to-earnings ratio of 44.81, a PEG ratio of 2.01 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company’s 50-day moving average price is $105.61 and its 200-day moving average price is $85.77.
Novo Nordisk A/S Increases Dividend
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 16th. Cantor Fitzgerald lifted their price objective on shares of Novo Nordisk A/S from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, TD Cowen lifted their price objective on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Monday, December 4th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $121.25.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.
- Five stocks we like better than Novo Nordisk A/S
- Why Invest in High-Yield Dividend Stocks?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Simpson Manufacturing stock doubled in value; It can double again
- How to Invest in Grocery Stores
- Uber quadruples EPS estimates, but is growth decelerating?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.